Biology Reference
In-Depth Information
[83] Hakim FT, Memon SA, Cepeda R, et al. Age-dependent incidence, time course, and
consequences of thymic renewal in adults. J Clin Invest 2005;115(4):930-9.
[84] Gattinoni L, Zhong XS, Palmer DC, et al. Wnt signaling arrests effector T cell differentia-
tion and generates CD8+ memory stem cells. Nat Med 2009;15(7):808-13.
[85] Mariotti J, Foley J, Jung U, et al. Ex vivo rapamycin generates apoptosis-resistant donor
Th2 cells that persist in vivo and prevent hemopoietic stem cell graft rejection. J Im-
munol 2008;180(1):89-105.
[86] Pua HH, Guo J, Komatsu M, He YW. Autophagy is essential for mitochondrial clearance
in mature T lymphocytes. J Immunol 2009;182(7):4046-55.
[87] Levine B, Mizushima N, Virgin HW. Autophagy in immunity and inflammation. Nature
2011;469(7330):323-35.
[88] Amarnath S, Fowler DH. Harnessing autophagy for adoptive T-cell therapy. Immuno-
therapy 2011;4(1):1-4.
[89] Foley JE, Mariotti J, Ryan K, Eckhaus M, Fowler DH. Th2 cell therapy of established
acute graft-versus-host disease requires IL-4 and IL-10 and is abrogated by IL-2 or host-
type antigen-presenting cells. Biol Blood Marrow Transplant 2008;14(9):959-72.
[90] Erdmann AA, Jung U, Foley JE, Toda Y, Fowler DH. Co-stimulated/Tc2 cells abrogate
murine marrow graft rejection. Biol Blood Marrow Transplant 2004;10(9):604-13.
[91] Mariotti J, Foley J, Ryan K, et al. Graft rejection as a Th1-type process amenable to
regulation by donor Th2-type cells through an interleukin-4/STAT6 pathway. Blood
2008;112(12):4765-75.
[92] Schwarer AP, Jiang YZ, Brookes PA, et al. Frequency of anti-recipient alloreactive helper
T-cell precursors in donor blood and graft-versus-host disease after HLA-identical
sibling bone-marrow transplantation. Lancet 1993;341(8839):203-5.
[93] Imami N, Brookes PA, Lombardi G, et al. Association between interleukin-4-producing
T lymphocyte frequencies and reduced risk of graft-versus-host disease. Transplanta-
tion 1998;65(7):979-88.
[94] Pan L, Delmonte Jr J, Jalonen CK, Ferrara JL. Pretreatment of donor mice with granulo-
cyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine
production and reduces severity of experimental graft-versus-host disease. Blood
1995;86(12):4422-9.
[95] Toh HC, Sun L, Soe Y, et al. G-CSF induces a potentially tolerant gene and immunophe-
notype profile in T cells in vivo. Clin Immunol 2009;132(1):83-92.
[96] Chu R, Brazauskas R, Kan F, et al. Comparison of outcomes after transplantation of
G-CSF-stimulated bone marrow grafts versus bone marrow or peripheral blood grafts
from HLA-matched sibling donors for patients with severe aplastic anemia. Biol Blood
Marrow Transplant 2011;17(7):1018-24.
[97] Fowler DH, Odom J, Steinberg SM, et al. Phase I clinical trial of costimulated, IL-4 po-
larized donor CD4+ T cells as augmentation of allogeneic hematopoietic cell transplan-
tation. Biol Blood Marrow Transplant 2006;12(11):1150-60.
[98] Hardy NM, Mossoba ME, Steinberg SM, et al. Phase I trial of adoptive cell transfer with
mixed-profile type-I/type-II allogeneic T cells for metastatic breast cancer. Clin Cancer
Res 2011;17(21):6878-87.
[99] Mossoba ME, Mariotti J, Yan XY, et al. T rapa cell clinical products contain a bal-
ance of minimally differentiated Th2/Th1 effector cells depleted of Treg cells. Blood
2010;116(21):158-9.
[100] Fowler DH, Mossoba ME, Hakim FT, et al. T rapa cell DLI safely balances Th1/Th2 cy-
tokine activation after low-intensity allogeneic hematopoietic cell transplantation. Biol
Blood Marrow Transplant 2011;17(2):S157.
244
Search WWH ::
Custom Search